Physician profile
Maya Thosani
NPI 1528248747
$2,342.66
in general payments reported to CMS, 2019-2025
28 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.92 · 2020: $118 · 2021: $142 · 2022: $241 · 2023: $488 · 2024: $624 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.98 | 2019-2025 | Botox |
| Galderma Laboratories, L.P. | $309.66 | 2022-2025 | Nemluvio |
| Lilly USA, LLC | $208.39 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $189.85 | 2024-2025 | |
| Steris Corporation | $185.97 | 2023 | |
| Sun Pharmaceutical Industries INC. | $149.39 | 2021-2025 | |
| Boston Scientific Corporation | $122.16 | 2023 | Apollo Esg System |
| Regeneron Healthcare Solutions, INC. | $115.93 | 2024-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $96.44 | 2023-2024 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $86.90 | 2022-2025 | Bimzelx |
| Amgen INC. | $81.95 | 2021-2024 | Otezla |
| Mimedx Group, INC. | $68.25 | 2025 | |
| Arcutis Biotherapeutics, INC. | $55.22 | 2024-2025 | Zoryve |
| Surgenex LLC | $40.52 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Dermavant Sciences, INC. | $37.64 | 2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $35.98 | 2024 | Adbry |
| Organon LLC | $30.06 | 2025 | Vtama |
| Organogenesis INC. | $29.77 | 2024 | |
| Kyowa Kirin, INC. | $29.74 | 2025 | |
| Nabriva Therapeutics, Plc | $24.63 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.97 | 2023 | Jublia |
| Journey Medical Corporation | $18.24 | 2023 | |
| Almirall LLC | $18.10 | 2025 | Klisyri |
| Dermira, INC. | $17.94 | 2019 | |
| Strata Skin Sciences, INC. | $15.13 | 2025 | Xtrac |
| Incyte Corporation | $15.12 | 2025 | Opzelura |
| Botanix Sb INC | $14.75 | 2025 | Sofdra |
| Pfizer INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Thosani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.